Integrated safety summary of single agent and combination margetuximab in phase 1, 2, and 3 studies of HER2-positive advanced cancers and metastatic breast cancer (MBC) Im, S., Cardoso, F., Cortes, J., Curigliano, G., Pegram, M. D., Rugo, H. S., Brown-Glaberman, U., Yardley, D. A., Kim, S., de Boer, M., Nowecki, Z., Glavicic, V., Wolf, I., Claes, N., Sohn, J., Bachelot, T., Kaufman, P. A., Baughman, J., Hong, S., Jacobs, K., Rock, E., Gradishar, W. J. AMER ASSOC CANCER RESEARCH. 2021

View details for Web of Science ID 000618737700274